Research Alliance Corp. I
Status: Deal Closed
U=S
| IPO Proceeds, $M | $135.70M |
|---|---|
| IPO Date | Jul 8, 2020 |
| CEO | Peter Kolchinsky, Ph.D. |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology |
| IPO Geography | Global |
| Target Company | POINT Biopharma |
| Deal Announced | Mar 15, 2021 |
| Deal Size, $M | $639.20M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Jun 29, 2021 |
| Amendment Vote | TBD |
| Closing Date | Jun 30, 2021 |
Formerly RACA
PNT
| Price | 12.5 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Research Alliance Corp. I:
- Structure and cap table
- 5 directors & officers
- 22 filings and events
- 1 underwriters
- 3 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Peter Kolchinsky, Ph.D. | 43 | Chief Executive Officer and Chairman |
| Matthew Hammond, Ph.D. | 31 | Chief Financial Officer and Director |
| Daniel S. Grau | 53 | Director |
| David C. Lubner | 56 | Director |
| Michael P. Gray | 49 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | BR | 11,800,000 | units |
| 11,800,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.